Kuros Biosciences Ltd.
Develops biologic technologies for tissue repair and bone regeneration.
KURN | SW
Overview
Corporate Details
- ISIN(s):
- CH0325814116
- LEI:
- 5299006U5POB2AVTT709
- Country:
- Switzerland
- Address:
- Wagisstraße 25, 8952 Schlieren
- Website:
- https://kurosbio.com/
- Sector:
- Manufacturing
Description
Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-27 01:00 |
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Tr…
|
English | 21.0 KB | ||
| 2023-11-28 18:00 |
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spina…
|
English | 16.5 KB | ||
| 2023-11-28 01:00 |
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spina…
|
English | 11.9 KB | ||
| 2023-10-12 07:00 |
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months…
|
English | 24.3 KB | ||
| 2023-10-12 02:00 |
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months…
|
English | 21.6 KB | ||
| 2023-08-09 07:00 |
Kuros Biosciences Reports Results for First Half 2023
|
English | 33.1 KB | ||
| 2023-08-09 02:00 |
Kuros Biosciences Reports Results for First Half 2023
|
English | 29.6 KB | ||
| 2023-07-13 19:29 |
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 …
|
English | 14.1 KB | ||
| 2023-07-13 02:00 |
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 …
|
English | 12.0 KB | ||
| 2023-05-08 17:18 |
Annual General Meeting of Kuros Biosciences approves all resolutions
|
English | 10.4 KB | ||
| 2023-05-08 02:00 |
Annual General Meeting of Kuros Biosciences approves all resolutions
|
English | 8.5 KB | ||
| 2023-04-27 07:00 |
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 20…
|
English | 16.6 KB | ||
| 2023-04-27 02:00 |
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 20…
|
English | 14.5 KB | ||
| 2023-03-15 07:00 |
Kuros Biosciences reports results for the full year 2022
|
English | 40.1 KB | ||
| 2023-03-15 01:00 |
Kuros Biosciences reports results for the full year 2022
|
English | 35.7 KB |
Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kuros Biosciences Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-23 | N/A | Executive member | Sell | None | 1,264,800.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 13,344.49 CHF |
| 2025-03-18 | N/A | Non-Executive member | Buy | None | 38,200.00 CHF |
| 2024-12-11 | N/A | Executive member | Sell | None | 4,702,500.00 CHF |
| 2024-11-15 | N/A | Non-Executive member | Buy | None | 925,210.00 CHF |
| 2024-11-14 | N/A | Non-Executive member | Sell | None | 592,000.00 CHF |
| 2024-11-12 | N/A | Executive member | Sell | None | 13,890.86 CHF |
| 2024-09-25 | N/A | Executive member | Sell | None | 8,226,000.00 CHF |
| 2024-09-25 | N/A | Non-Executive member | Sell | None | 3,656,000.00 CHF |
| 2024-09-24 | N/A | Non-Executive member | Buy | None | 223,720.00 CHF |
Peer Companies
